Literature DB >> 31470068

The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study.

Alina M Allen1, Stephen B Hicks2, Kristin C Mara3, Joseph J Larson3, Terry M Therneau3.   

Abstract

BACKGROUND & AIMS: Cancer is a major cause of death in patients with non-alcoholic fatty liver disease (NAFLD). Obesity is a risk factor for cancers; however, the role of NAFLD in this association is unknown. We investigated the effect of NAFLD versus obesity on incident cancers.
METHODS: We identified all incident cases of NAFLD in a US population between 1997-2016. Individuals with NAFLD were matched by age and sex to referent individuals from the same population (1:3) on the index diagnosis date. We ascertained the incidence of cancer after index date until death, loss to follow-up or study end. NAFLD and cancer were defined using a code-based algorithm with high validity and tested by medical record review. The association between NAFLD or obesity and cancer risk was examined using Poisson regression.
RESULTS: A total of 4,722 individuals with NAFLD (median age 54, 46% male) and 14,441 age- and sex-matched referent individuals were followed for a median of 8 (range 1-21) years, during which 2,224 incident cancers occurred. NAFLD was associated with 90% higher risk of malignancy: incidence rate ratio (IRR) = 1.9 (95% CI 1.3-2.7). The highest risk increase was noted in liver cancer, IRR = 2.8 (95% CI 1.6-5.1), followed by uterine IRR = 2.3 (95% CI 1.4-4.1), stomach IRR = 2.3 (95% CI 1.3-4.1), pancreas IRR = 2.0 (95% CI 1.2-3.3) and colon cancer IRR = 1.8 (95% CI 1.1-2.8). In reference to non-obese controls, NAFLD was associated with a higher risk of incident cancers (IRR = 2.0, 95% CI 1.5-2.9), while obesity alone was not (IRR = 1.0, 95% CI 0.8-1.4).
CONCLUSIONS: NAFLD was associated with increased cancer risk, particularity of gastrointestinal types. In the absence of NAFLD, the association between obesity and cancer risk is small, suggesting that NAFLD may be a mediator of the obesity-cancer association. LAY
SUMMARY: We studied the incidence of malignancies in a community cohort of adults with non-alcoholic fatty liver disease (NAFLD) in reference to age- and sex-matched adults without NAFLD. After 21 years of longitudinal follow-up, NAFLD was associated with a nearly 2-fold increase in the risk of developing cancers, predominantly of the liver, gastrointestinal tract and uterus. The association with increased cancer risk was stronger in NAFLD than obesity.
Copyright © 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Epidemiology; NAFLD; NASH; Natural history; Outcomes

Year:  2019        PMID: 31470068      PMCID: PMC6921701          DOI: 10.1016/j.jhep.2019.08.018

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  29 in total

Review 1.  Epidemiologic trends in overweight and obesity.

Authors:  Cynthia L Ogden; Margaret D Carroll; Katherine M Flegal
Journal:  Endocrinol Metab Clin North Am       Date:  2003-12       Impact factor: 4.741

Review 2.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms.

Authors:  Eugenia E Calle; Rudolf Kaaks
Journal:  Nat Rev Cancer       Date:  2004-08       Impact factor: 60.716

3.  Recent Trends in the Epidemiology of Hepatocellular Carcinoma in Olmsted County, Minnesota: A US Population-based Study.

Authors:  Ju Dong Yang; Hager Ahmed Mohammed; William S Harmsen; Felicity Enders; Gregory J Gores; Lewis R Roberts
Journal:  J Clin Gastroenterol       Date:  2017-09       Impact factor: 3.062

4.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study.

Authors:  Leon A Adams; James F Lymp; Jenny St Sauver; Schuyler O Sanderson; Keith D Lindor; Ariel Feldstein; Paul Angulo
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

Review 5.  Non-alcoholic fatty liver disease - A global public health perspective.

Authors:  Zobair M Younossi
Journal:  J Hepatol       Date:  2018-11-09       Impact factor: 25.083

6.  Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota.

Authors:  M Conio; A J Cameron; Y Romero; C D Branch; C D Schleck; L J Burgart; A R Zinsmeister; L J Melton; G R Locke
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

Review 7.  Obesity and cancer--mechanisms underlying tumour progression and recurrence.

Authors:  Jiyoung Park; Thomas S Morley; Min Kim; Deborah J Clegg; Philipp E Scherer
Journal:  Nat Rev Endocrinol       Date:  2014-06-17       Impact factor: 43.330

8.  Body fat distribution and risk of coronary heart disease in men and women in the European Prospective Investigation Into Cancer and Nutrition in Norfolk cohort: a population-based prospective study.

Authors:  Dexter Canoy; S Matthijs Boekholdt; Nicholas Wareham; Robert Luben; Ailsa Welch; Sheila Bingham; Iain Buchan; Nicholas Day; Kay-Tee Khaw
Journal:  Circulation       Date:  2007-12-10       Impact factor: 29.690

Review 9.  Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

Authors:  Zobair M Younossi; Aaron B Koenig; Dinan Abdelatif; Yousef Fazel; Linda Henry; Mark Wymer
Journal:  Hepatology       Date:  2016-02-22       Impact factor: 17.425

Review 10.  History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population.

Authors:  Walter A Rocca; Barbara P Yawn; Jennifer L St Sauver; Brandon R Grossardt; L Joseph Melton
Journal:  Mayo Clin Proc       Date:  2012-11-28       Impact factor: 7.616

View more
  38 in total

1.  The "obese liver" and gastrointestinal cancer risk.

Authors:  Amedeo Lonardo; Luca Roncucci
Journal:  Transl Gastroenterol Hepatol       Date:  2020-07-05

Review 2.  Does Nonalcoholic Fatty Liver Disease Increase the Risk for Extrahepatic Malignancies?

Authors:  Somaya Albhaisi; Arun J Sanyal
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-04-13

Review 3.  Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease.

Authors:  Michelle T Long; Sanil Gandhi; Rohit Loomba
Journal:  Metabolism       Date:  2020-05-05       Impact factor: 8.694

4.  Tumor Incidence in Patients with Non-Alcoholic Fatty Liver Disease.

Authors:  Yvonne Huber; Christian Labenz; Maurice Michel; Marcus-A Wörns; Peter R Galle; Karel Kostev; Jörn M Schattenberg
Journal:  Dtsch Arztebl Int       Date:  2020-10-23       Impact factor: 5.594

5.  Dehydroabietic acid improves nonalcoholic fatty liver disease through activating the Keap1/Nrf2-ARE signaling pathway to reduce ferroptosis.

Authors:  Gai Gao; Zhishen Xie; Er-Wen Li; Yong Yuan; Yu Fu; Pan Wang; Xiaowei Zhang; Yonghui Qiao; Jiangyan Xu; Christian Hölscher; Hui Wang; Zhenqiang Zhang
Journal:  J Nat Med       Date:  2021-02-15       Impact factor: 2.343

6.  What's new in non-alcoholic fatty liver disease?

Authors:  Jessica Spiers; James Hallimond Brindley; Wenhao Li; William Alazawi
Journal:  Frontline Gastroenterol       Date:  2022-05-31

Review 7.  Clinical Phenotyping and the Application of Precision Medicine in MAFLD.

Authors:  Saad Saffo; Albert Do
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-05-23

8.  Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.

Authors:  Tracey G Simon; Bjorn Roelstraete; Hamed Khalili; Hannes Hagström; Jonas F Ludvigsson
Journal:  Gut       Date:  2020-10-09       Impact factor: 23.059

9.  Outcomes of excessive alcohol drinkers without baseline evidence of chronic liver disease after 15 years follow-up: Heavy burden of cancer and liver disease mortality.

Authors:  Sónia Bernardo; Ricardo Crespo; Sofia Saraiva; Rui Barata; Sara Gonçalves; Paulo Nogueira; Helena Cortez-Pinto; Mariana Verdelho Machado
Journal:  PLoS One       Date:  2021-05-25       Impact factor: 3.240

10.  Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality.

Authors:  Tracey G Simon; Bjorn Roelstraete; Kayla Hartjes; Uzma Shah; Hamed Khalili; Henrik Arnell; Jonas F Ludvigsson
Journal:  J Hepatol       Date:  2021-07-03       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.